FDA Approves Emergent’s New rFIX Therapy!

In late April, Emergent BioSolutions, Inc., announced that the US Food and Drug Administration (FDA) has approved IXINITY®, the company’s recombinant factor IX (rFIX) product. IXINITY® is indicated for the control and prevention of bleeding episodes and for perioperative management in adults and children, 12 years of age or older, with hemophilia B. Read more details here.

Did you like this? Share it: